大剂量舍尼通治疗轻中度良性前列腺增生尿动力学评价

目的 利用尿动力学检查评价大剂量舍尼通治疗轻中度良性前列腺增生的疗效.方法 80例轻中度良性前列腺增生患者7分＜国际前列腺症状评分(IPSS)≤20分]口服舍尼通1年,每次750mg,每日3次;在治疗前、治疗后3、6及12个月通过IPSS、最大尿流率(Qmax)测定、残余尿量(PVR)测定、压力-流率(A-G)检查评价疗效.结果 80例患者随访(1.2±1.6)年,其中26例退出试验,54例患者治疗前IPSS为(20.5±4.5)分,PVR为(42.5±8.2)ml,Qmax为(10.2±2.3)ml/s,A-G值为56.5±12.8、最大尿流率时逼尿肌压力(PQmax1)为(54.8±13.7)mmHg(1mmHg=0.133kPa).治疗后12个月IPSS为(11.0±3.3)分,PVR为(15.9±7.4)ml,Qmax为(15.7±2.5)ml/s,A-G值为49.2±13.6,PQmax为(43.6±14.9)mmHg.治疗后12个月较治疗前Qmax有明显提高(P＜0.05),PVR、IPSS、A-G值、PQmax明显下降(P＜0.05).结论 大剂量舍尼通治疗良性前列腺增生疗效满意,治疗后各项尿动力学检查参数明显改善.

Effectiveness of the treatment of slight and moderate benign prostatic hyperplasia with large doses of cernilton by urodynamic test

Objective To evaluate the effectiveness of the treatment of slight and moderate benign prostatic hyperplasia(BPH)with large doses of cemilton by urodynamie test.Methods A systematic review of using large doses of cernihon only for 80 patients with BPH with 7 grade ＜ International Prostate Symptom Score(IPSS)≤20 grade.All cases with cemilton had been administered in a dosage of 750 mg,three times a day for one year.All were respectively given IPSS,postvoiding residual urine(PVR),maximum flow rate(Qmax)and pressure-flow(A-G)test in order to assess the effectiveness at pre-treatment and 3,6,12 months after treatment.Results All patients had followed up for(1.2±1.6)years,additionally 26 of those were removed and others had received complete follow-up.Before the treatment IPSS was(20.5±4.5)grade,PVR was(42.5±8.2)ml,Qmax was(10.2±2.3)ml/s,A-G was 56.5±12.8,PQmax was (54.8±13.7)mm Hg(1 mm Hg = 0.133 kPa),and 12 months later,IPSS was(11.0±3.3)grade,PVR was (15.9±7.4)ml,Qmax was(15.7±2.5)ml/s,A-G was 49.2±13.6,PQmax was(43.6±14.9)mm Hg.There were significantly difference between pre-treatment and post-treatment data of the urodynamics(P ＜ 0.05).Conclusions The effectiveness of the treatment of slight and moderate benign prostatic hyperplasia with large doses of cemihon are relatively satisfactory.Main post-treatment urodynamic parameters obviously improves than that of the pre-treatment.